VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- Eldorado Gold Corporation (“Eldorado” or “the Company”) announces that it has received approval from the Toronto Stock Exchange (the "TSX") of Eldorado’s notice of intention to renew its normal course issuer bid (the "NCIB"). Pursuant to the NCIB, Eldorado may purchase up to 10,159,967 common shares of Eldorado ("Common Shares"), which is 5% of the 203,199,350 issued and outstanding Common Shares as at July 30, 2025. Purchases will be made throu ...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES (Note: All dollar amounts in this press release are expressed in U.S. dollars except as otherwise noted. The financial results are derived from unaudited financial statements prepared using the recognition and measurement requirements of International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS® Accounting Standards"), except as otherwise noted. This press release contains ...

Core Viewpoint - Pacific Health Care Organization, Inc. reported significant financial growth in its quarterly results for the period ending June 30, 2025, indicating improved operational efficiency and profitability compared to the same period in the previous year [1][2][3]. Financial Performance - Total revenues for the quarter ended June 30, 2025, were $1,726,541, an increase from $1,541,087 for the same quarter in 2024, reflecting a year-over-year growth of approximately 12% [2]. - Income from operations rose to $303,559 for the quarter ended June 30, 2025, compared to $191,995 for the same quarter in 2024, marking an increase of about 58% [2]. - Net income for the quarter was $636,907, or $0.05 per weighted average share, compared to $215,556, or $0.02 per share, for the same quarter in 2024, representing a substantial increase in profitability [3]. Cash Flow Analysis - Net cash provided by operating activities for the six months ended June 30, 2025, was $785,838, a significant increase of $642,190 compared to $143,648 for the same period in 2024 [3]. - Net cash used in investing activities was ($664,536) for the six months ended June 30, 2025, compared to ($181,963) for the same period in 2024, primarily due to the purchase of US Treasury Bills [4]. - Net cash used in financing activities was $35,930 for the six months ended June 30, 2025, a shift from $105,915 of cash provided by financing activities during the same period in 2024, attributed to the maturation of an insurance financing agreement [5]. Company Overview - Pacific Health Care Organization, Inc. specializes in workers' compensation cost containment, aiming to reduce medical claims expenses while ensuring high-quality healthcare for injured employees [7]. - The company offers a range of services, including Health Care Organizations, Medical Provider Networks, medical case management, utilization review, medical bill review, and Medicare set-aside services, which can be provided as bundled solutions or standalone services [7].

Core Viewpoint - Arhaus, Inc. is set to release its second quarter 2025 financial results on August 7, 2025, before the market opens, followed by a conference call to discuss these results [1] Company Overview - Arhaus, founded in 1986, is a lifestyle brand and omni-channel retailer specializing in premium artisan-crafted home furnishings [3] - The company employs a proprietary model that involves direct design and sourcing from leading manufacturers and artisans globally, offering heirloom quality products that are sustainably sourced and built to last [3] - Arhaus operates over 100 showroom and design studio locations across the United States and provides complimentary in-home design services through a team of interior designers [3] - The company is recognized for its innovative design, responsible sourcing, and client-first service [3] Investor Communication - A live webcast of the upcoming conference call will be available at ir.arhaus.com, with participation options provided for both U.S. and international callers [2] - A telephone replay of the call will be accessible for one week, and a webcast replay will be available for approximately 12 months [2]

Financial Results Announcement - Coherus Oncology will release its second quarter 2025 financial results after market close on August 7, 2025 [1] - A conference call and webcast will be hosted by Coherus' management team starting at 5:00 p.m. EDT on the same day to discuss the financial results and provide a business update [1][3] Webcast and Access Information - A replay of the webcast will be available on the Coherus investor website following the live conference call [2] - The press release with the financial results and related materials will be accessible on the investor website before the conference call begins [3] Company Overview - Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved PD-1 inhibitor, LOQTORZI, and a promising pipeline including two mid-stage clinical candidates targeting various cancers [6] - The company aims to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance new indications in combination with pipeline candidates and partners [6] Pipeline and Research Focus - Coherus' pipeline includes multiple antibody immunotherapy candidates designed to enhance immune responses against tumors [7] - CHS-114, a selective anti-CCR8 antibody, is in Phase 1b studies for advanced solid tumors, while Casdozokitug, an IL-27 antagonistic antibody, is being evaluated in multiple studies for various cancers [7]

Core Insights - Mercer International Inc. reported a significant decline in Operating EBITDA, posting negative $20.9 million for Q2 2025, down from positive $30.4 million in Q2 2024 and $47.1 million in Q1 2025 [2][9][37] - The company experienced a net loss of $86.1 million ($1.29 per share) in Q2 2025, compared to a net loss of $67.6 million ($1.01 per share) in Q2 2024 and $22.3 million ($0.33 per share) in Q1 2025 [2][9][37] - The decline in performance is attributed to ongoing uncertainties in the global trade environment, weaker demand for pulp in China, and a depreciation of the dollar, which negatively impacted Operating EBITDA by approximately $26 million [3][9][37] Financial Performance - Total revenues for Q2 2025 decreased by approximately 9% to $453.5 million from $499.4 million in Q2 2024, primarily due to lower sales realizations and volumes from pulp and manufactured products, partially offset by higher lumber sales realizations [14][35] - Costs and expenses in Q2 2025 decreased by approximately 6% to $511.9 million from $543.2 million in Q2 2024, driven by fewer days of planned maintenance downtime at pulp mills [15][35] - The company reported a total net loss of $108.4 million for the first half of 2025, compared to a net loss of $84.3 million in the same period of 2024 [36][48] Segment Analysis - In the pulp segment, revenues decreased by approximately 10% to $332.3 million in Q2 2025 from $367.4 million in Q2 2024, primarily due to lower pulp sales realizations and volumes [19][22] - The solid wood segment saw revenues decrease by approximately 10% to $117.3 million in Q2 2025 from $130.2 million in Q2 2024, mainly due to lower manufactured products revenues, despite higher lumber revenues [28][29] - Lumber revenues increased by approximately 23% to $66.3 million in Q2 2025 from $53.9 million in Q2 2024, driven by higher sales realizations [29][30] Operational Highlights - The company had 29 days of downtime in Q2 2025, which included 23 days of planned annual maintenance and six additional days due to slower than expected start-up [11][25] - Total pulp production increased by approximately 8% to 457,117 ADMTs in Q2 2025 compared to 421,692 ADMTs in Q2 2024, attributed to fewer days of planned maintenance downtime [24][25] - Average per unit fiber costs increased by approximately 11% in Q2 2025 compared to Q2 2024, primarily due to higher costs at German mills [26][34] Strategic Initiatives - The company is implementing cost reduction initiatives under the "One Goal One Hundred" program, targeting $100 million in profitability improvement actions by the end of 2026, with approximately $5 million in cost savings realized to date [5][9] - The quarterly dividend has been suspended to prudently allocate capital amidst ongoing market uncertainties [9][12]

AUSTIN, Texas , July 31, 2025 (GLOBE NEWSWIRE) -- Astrotech Corporation (Nasdaq: ASTC), a provider of next generation security screening and detection technologies based on Mass Spectrometry (“Mass Spec”), today announced the first sale and deployment of its TRACER 1000™ Narcotics Trace Detector (“TRACER 1000 NTD™”) in Vietnam, by way of its subsidiary 1st Detect. This milestone marks a significant step in expanding the 1st Detect footprint across Southeast Asia and reinforces its commitment to enhancing na ...

Ambiq Upsized Initial Public Offering Ambiq NYSE AMBQ AUSTIN, Texas, July 31, 2025 (GLOBE NEWSWIRE) -- Ambiq Micro, Inc. (“Ambiq”), a technology leader in ultra-low-power semiconductor solutions for edge AI, today announced the closing of its upsized initial public offering of 4,600,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase 600,000 additional shares, at a public offering price of $24.00 per share. The gross proceeds to Ambiq from the offering, be ...

Company Overview - authID is a leading provider of biometric identity verification and authentication solutions, ensuring enterprises "Know Who's Behind the Device™" for every customer or employee login and transaction [4] - The company offers a patented biometric identity platform that powers biometric identity proofing in 700 milliseconds and biometric authentication in 25 milliseconds [4] - authID's PrivacyKey solution boasts a false match rate of 1-to-1 billion while storing no biometric data, effectively stopping fraud at onboarding and preventing account takeovers [4] Financial Results Announcement - authID will report its financial results for the second quarter ended June 30, 2025, on August 14, 2025, after market close [1] - Following the earnings release, the CEO Rhon Daguro and CFO Ed Sellitto will host a webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update [1] Conference Call Participation - Participants can access a registration link to join the live conference call, with a recommendation to dial in 15 minutes early to avoid delays [2] - A live webcast of the call will also be available on the company's website [2] Event Replay - A replay of the event and a copy of the presentation will be available for 90 days at authID's Investor Relations Events [3]

Conference Call to be held on August 14th, 2025 at 5:00 PM ESTNEW HAVEN, Conn., July 31, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2025 corporate update call on August 14th, 2025 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. The conference call may be accessed by calling 800.717.1738. All callers should ask for the Precipio conference call. Listeners interested in submitting questions in ...